(WORX) Scworx - Ratings and Ratios

SCWorx Corp. (NASDAQ:WORX) is a healthcare technology company focused on developing and marketing IT solutions designed to optimize operational workflows and data management within healthcare facilities. The companys product suite includes software tools for virtualized item master file management, electronic medical records, charge description master automation, contract management, and rebate management. Additionally, SCWorx offers ScanWorx, a solution for managing and integrating data from multiple sources, as well as big data analytics and modeling to support informed decision-making. Its services also extend to data normalization, interoperability, and integration of acquired businesses, addressing critical pain points in healthcare IT infrastructure.

The company primarily targets hospitals and health systems, leveraging a combination of direct sales and partnerships with distributors and resellers. SCWorx is headquartered in Tampa, Florida, and operates in the highly competitive Health Care Technology sector. Its solutions aim to address inefficiencies in healthcare data management, reducing administrative burdens and improving operational outcomes for its clients. For more information, visit their website at https://www.scworx.com.

3-Month Forecast: Based on and , SCWorx Corp. (WORX) is expected to face continued challenges in the near term. The stock has shown declining momentum, with its SMA 20, 50, and 200 all trending downward, currently at 1.10, 1.44, and 1.44, respectively. The average trading volume of 38,500 shares over the last 20 days indicates limited market interest. With a last price of $0.75 and an ATR of 0.11, the stock is expected to remain volatile but within a narrow range. From a perspective, the companys market cap of $1.72M and P/S ratio of 0.53 suggest undervaluation relative to peers, but the lack of profitability (P/E: 0.00) and RoE (None) raise concerns about its ability to generate returns. Over the next three months, WORX may struggle to gain traction, but its low valuation and niche focus could attract speculative interest from value investors.